Literature DB >> 7858153

Autocrine and paracrine functions of cytokines in malignant lymphomas.

S M Hsu1, P L Hsu.   

Abstract

Cytokines play important roles in the pathogenesis of lymphomas via an autocrine or a paracrine mechanism, or both. The characteristic clinical and histopathological features of malignant lymphomas may be due in part to elevated serum or tissue levels of cytokines. Determination of the effects of cytokines on the growth or differentiation of lymphoma cells is often complicated by the fact that more than one cytokine is responsible, and by the failure of anti-cytokine antibodies or antisense oligonucleotides to block the proliferation in vitro of lymphoma cells. However, it appears that IL-6 and/or IL-9 may play a prominent role in the tumor cell proliferation of Hodgkin's disease (HD), anaplastic large-cell lymphoma, or immunoblastic lymphoma. IL-6 may also be responsible for the plasmacytoid differentiation of lymphoma cells in polymorphic immunocytoma. The histopathological changes as a result of paracrine effects are most noticeable in HD. The malignant (H-RS) cells of HD have been shown to express IL-1, IL-5, IL-6, IL-9, TNF-alpha, M-CSF, TGF-beta, and CD80, and, less frequently, IL-4 and G-CSF. These cytokines may be responsible for the increased cellular reaction and fibrosis observed in tissues involved by HD and for the immunosuppression found in patients with HD. In contrast to H-RS cells, most non-HD lymphoma cells do not produce cytokines in excess amounts and reveal only a minimal cellular reaction. Exceptions include T-cell-rich B-cell lymphoma, angiocentric T-cell lymphoma, and angio-immunoblastic lymphadenopathy (AILD-like T-cell lymphoma. IL-4 is responsible for the T-cell reaction in T-cell-rich B-cell lymphoma, whereas IL-6 accounts for the plasma cell reaction in AILD-type T-cell lymphoma. The authors extensively review the role of cytokines in lymphomas because this may lead to major advances in the understanding of the molecular processes involved in the histopathogenesis of lymphomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858153     DOI: 10.1016/0753-3322(94)90004-3

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

Review 1.  G-CSF-producing gastric anaplastic large cell lymphoma complicating esophageal cancer.

Authors:  M Sugimoto; M Kajimura; H Hanai; N Shirai; F Tanioka; E Kaneko
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

2.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma.

Authors:  Mark P Purdue; Qing Lan; Rachel Bagni; William G Hocking; Dalsu Baris; Douglas J Reding; Nathaniel Rothman
Journal:  Cancer Res       Date:  2011-06-01       Impact factor: 12.701

3.  Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.

Authors:  Marie-Hélène Delfau-Larue; Laurence de Leval; Bertrand Joly; Anne Plonquet; Dominique Challine; Marie Parrens; Alain Delmer; Gilles Salles; Franck Morschhauser; Richard Delarue; Pauline Brice; Reda Bouabdallah; Olivier Casasnovas; Hervé Tilly; Philippe Gaulard; Corinne Haioun
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

4.  Targeted ovarian cancer treatment: the TRAILs of resistance.

Authors:  Nadzeya Goncharenko Khaider; Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

Review 5.  Sarcomatoid variant of ALK- anaplastic large cell lymphoma involving multiple lymph nodes and both lungs with production of proinflammatory cytokines: report of a case and review of literature.

Authors:  Lu Yu; Lin Li Yan; Shou Jing Yang
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

6.  Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.

Authors:  Denis Lane; Isabelle Matte; Claudine Rancourt; Alain Piché
Journal:  BMC Cancer       Date:  2011-05-30       Impact factor: 4.430

7.  CSBF/C10orf99, a novel potential cytokine, inhibits colon cancer cell growth through inducing G1 arrest.

Authors:  Wen Pan; Yingying Cheng; Heyu Zhang; Baocai Liu; Xiaoning Mo; Ting Li; Lin Li; Xiaojing Cheng; Lianhai Zhang; Jiafu Ji; Pingzhang Wang; Wenling Han
Journal:  Sci Rep       Date:  2014-10-29       Impact factor: 4.379

8.  The Prognostic Role of Circulating Epstein-Barr Virus DNA Copy Number in Angioimmunoblastic T-Cell Lymphoma Treated with Dose-Adjusted EPOCH.

Authors:  Jin-Hua Liang; Luo Lu; Hua-Yuan Zhu; Wang Li; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Res Treat       Date:  2018-04-02       Impact factor: 4.679

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.